Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study. (Greko II)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02101684
Recruitment Status : Terminated (Slow recruitment rate)
First Posted : April 2, 2014
Last Update Posted : March 5, 2018
Information provided by (Responsible Party):
Grupo Español de Tumores Huérfanos e Infrecuentes

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : January 11, 2017
  Actual Study Completion Date : January 11, 2017